Watch our 3 minute interview at BIO-Europe 2025.

Hi. My name is Nick Hutchinson. I'm Associate Vice President Business Development for Just - Evotec Biologics. 

What brings your company to this event, and what are you showcasing today?

Just - Evotec Biologics is at BIO-Europe because it brings together lots of very innovative biotechnology companies from around the world. So, not just Europe but from North America, Middle East, and Asia. Just - Evotec Biologics is showcasing our biologic CDMO services for the manufacturing of antibody and related biotherapeutics. 

What recent innovations or partnerships are you most excited about?

I'm particularly excited right now about the fact that we are out-licensing our unique continuous manufacturing technology. So that includes perfusion-ready cell lines, perfusion media, and our continuous biomanufacturing platform automation so that companies can establish their own manufacturing capabilities at their facilities or at new locations, whether they want to do that in North America, Europe, or around the world. 

How is your company helping to solve current challenges in the industry?

Just - Evotec Biologic is solving kind of two different types of challenges for companies that are looking to commercialize antibody biotherapeutics. On the one hand, with your more standard IgG1, IgG4 formats, we're really looking to reduce the cost of goods manufactured. But what we're also seeing with the continuous manufacturing platform is that it was working really well with these novel, complex antibody formats, which often are more fragile. So, the fact that the process is continuous means that there's less opportunity for the antibody to degrade, so we see higher yields and a higher product quality. And really allowing some of these novel antibodies to be commercialized in a way that they would really struggle with from a CMC perspective. 

What kind of partners or collaborators are you looking to connect with here?

We are looking to connect with companies with antibody biologics, IgG1s and IgG4s. But also those companies with more complex antibodies such as bispecifics, multi-specifics, even FC fusion proteins. Whether they need manufacturing for clinical development or even for commercial manufacturing.

What’s next for your company in the coming year?

Over the coming year, we're looking to out-license more of our technology and help companies establish this unique, innovative, continuous manufacturing technologies in their own facilities at their own locations across locations around the world so we can expand access to biotherapeutics and try and get those to as many patients as possible. 

Thank you and please check out our website or get in contact if you'd like more information about our services.